Medical - Devices
Compare Stocks
2 / 10Stock Comparison
BRKR vs WAT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
BRKR vs WAT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Devices | Medical - Diagnostics & Research |
| Market Cap | $5.77B | $20.38B |
| Revenue (TTM) | $3.44B | $3.77B |
| Net Income (TTM) | $-9M | $449M |
| Gross Margin | 46.6% | 55.0% |
| Operating Margin | 5.4% | 17.1% |
| Forward P/E | 18.0x | 23.8x |
| Total Debt | $2.25B | $1.41B |
| Cash & Equiv. | $183M | $588M |
BRKR vs WAT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Bruker Corporation (BRKR) | 100 | 87.8 | -12.2% |
| Waters Corporation (WAT) | 100 | 171.4 | +71.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BRKR vs WAT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BRKR is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 3 yrs, beta 1.59, yield 0.5%
- Rev growth 13.6%, EPS growth -73.8%, 3Y rev CAGR 11.7%
- 13.6% revenue growth vs WAT's 7.0%
WAT carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 161.3% 10Y total return vs BRKR's 46.2%
- Lower volatility, beta 1.07, Low D/E 55.0%
- Beta 1.07
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 13.6% revenue growth vs WAT's 7.0% | |
| Value | Lower P/E (18.0x vs 23.8x) | |
| Quality / Margins | 11.9% margin vs BRKR's -0.3% | |
| Stability / Safety | Beta 1.07 vs BRKR's 1.59, lower leverage | |
| Dividends | 0.5% yield; 3-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | -1.7% vs BRKR's -6.2% | |
| Efficiency (ROA) | 4.6% ROA vs BRKR's -0.1%, ROIC 20.3% vs 6.1% |
BRKR vs WAT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
BRKR vs WAT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
WAT leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
WAT and BRKR operate at a comparable scale, with $3.8B and $3.4B in trailing revenue. WAT is the more profitable business, keeping 11.9% of every revenue dollar as net income compared to BRKR's -0.3%. On growth, WAT holds the edge at +91.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $3.4B | $3.8B |
| EBITDAEarnings before interest/tax | $407M | $953M |
| Net IncomeAfter-tax profit | -$9M | $449M |
| Free Cash FlowCash after capex | $43M | $264M |
| Gross MarginGross profit ÷ Revenue | +46.6% | +55.0% |
| Operating MarginEBIT ÷ Revenue | +5.4% | +17.1% |
| Net MarginNet income ÷ Revenue | -0.3% | +11.9% |
| FCF MarginFCF ÷ Revenue | +1.3% | +7.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -0.2% | +91.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +8.9% | -142.9% |
Valuation Metrics
BRKR leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 31.8x trailing earnings, WAT trades at a 36% valuation discount to BRKR's 50.0x P/E. On an enterprise value basis, BRKR's 17.9x EV/EBITDA is more attractive than WAT's 19.3x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $5.8B | $20.4B |
| Enterprise ValueMkt cap + debt − cash | $7.8B | $21.2B |
| Trailing P/EPrice ÷ TTM EPS | 50.01x | 31.83x |
| Forward P/EPrice ÷ next-FY EPS est. | 17.98x | 23.82x |
| PEG RatioP/E ÷ EPS growth rate | — | 6.15x |
| EV / EBITDAEnterprise value multiple | 17.92x | 19.29x |
| Price / SalesMarket cap ÷ Revenue | 1.71x | 6.44x |
| Price / BookPrice ÷ Book value/share | 3.13x | 7.98x |
| Price / FCFMarket cap ÷ FCF | 42.39x | 37.76x |
Profitability & Efficiency
WAT leads this category, winning 9 of 9 comparable metrics.
Profitability & Efficiency
WAT delivers a 8.0% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $-0 for BRKR. WAT carries lower financial leverage with a 0.55x debt-to-equity ratio, signaling a more conservative balance sheet compared to BRKR's 1.24x. On the Piotroski fundamental quality scale (0–9), WAT scores 4/9 vs BRKR's 3/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -0.3% | +8.0% |
| ROA (TTM)Return on assets | -0.1% | +4.6% |
| ROICReturn on invested capital | +6.1% | +20.3% |
| ROCEReturn on capital employed | +6.7% | +18.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 1.24x | 0.55x |
| Net DebtTotal debt minus cash | $2.1B | $820M |
| Cash & Equiv.Liquid assets | $183M | $588M |
| Total DebtShort + long-term debt | $2.2B | $1.4B |
| Interest CoverageEBIT ÷ Interest expense | 2.35x | 6.72x |
Total Returns (Dividends Reinvested)
WAT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in WAT five years ago would be worth $11,104 today (with dividends reinvested), compared to $5,648 for BRKR. Over the past 12 months, WAT leads with a -1.7% total return vs BRKR's -6.2%. The 3-year compound annual growth rate (CAGR) favors WAT at 4.9% vs BRKR's -21.1% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -20.9% | -10.3% |
| 1-Year ReturnPast 12 months | -6.2% | -1.7% |
| 3-Year ReturnCumulative with dividends | -50.8% | +15.4% |
| 5-Year ReturnCumulative with dividends | -43.5% | +11.0% |
| 10-Year ReturnCumulative with dividends | +46.2% | +161.3% |
| CAGR (3Y)Annualised 3-year return | -21.1% | +4.9% |
Risk & Volatility
WAT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
WAT is the less volatile stock with a 1.07 beta — it tends to amplify market swings less than BRKR's 1.59 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. WAT currently trades 82.7% from its 52-week high vs BRKR's 67.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.59x | 1.07x |
| 52-Week HighHighest price in past year | $56.22 | $414.15 |
| 52-Week LowLowest price in past year | $28.53 | $275.05 |
| % of 52W HighCurrent price vs 52-week peak | +67.6% | +82.7% |
| RSI (14)Momentum oscillator 0–100 | 46.0 | 43.8 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 981K |
Analyst Outlook
BRKR leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates BRKR as "Buy" and WAT as "Hold". Consensus price targets imply 37.1% upside for BRKR (target: $52) vs 17.5% for WAT (target: $403). BRKR is the only dividend payer here at 0.53% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $52.13 | $402.57 |
| # AnalystsCovering analysts | 32 | 34 |
| Dividend YieldAnnual dividend ÷ price | +0.5% | — |
| Dividend StreakConsecutive years of raises | 3 | 1 |
| Dividend / ShareAnnual DPS | $0.20 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% |
WAT leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BRKR leads in 2 (Valuation Metrics, Analyst Outlook).
BRKR vs WAT: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is BRKR or WAT a better buy right now?
For growth investors, Bruker Corporation (BRKR) is the stronger pick with 13.
6% revenue growth year-over-year, versus 7. 0% for Waters Corporation (WAT). Waters Corporation (WAT) offers the better valuation at 31. 8x trailing P/E (23. 8x forward), making it the more compelling value choice. Analysts rate Bruker Corporation (BRKR) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BRKR or WAT?
On trailing P/E, Waters Corporation (WAT) is the cheapest at 31.
8x versus Bruker Corporation at 50. 0x. On forward P/E, Bruker Corporation is actually cheaper at 18. 0x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — BRKR or WAT?
Over the past 5 years, Waters Corporation (WAT) delivered a total return of +11.
0%, compared to -43. 5% for Bruker Corporation (BRKR). Over 10 years, the gap is even starker: WAT returned +161. 3% versus BRKR's +46. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BRKR or WAT?
By beta (market sensitivity over 5 years), Waters Corporation (WAT) is the lower-risk stock at 1.
07β versus Bruker Corporation's 1. 59β — meaning BRKR is approximately 48% more volatile than WAT relative to the S&P 500. On balance sheet safety, Waters Corporation (WAT) carries a lower debt/equity ratio of 55% versus 124% for Bruker Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — BRKR or WAT?
By revenue growth (latest reported year), Bruker Corporation (BRKR) is pulling ahead at 13.
6% versus 7. 0% for Waters Corporation (WAT). On earnings-per-share growth, the picture is similar: Waters Corporation grew EPS 0. 5% year-over-year, compared to -73. 8% for Bruker Corporation. Over a 3-year CAGR, BRKR leads at 11. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BRKR or WAT?
Waters Corporation (WAT) is the more profitable company, earning 20.
3% net margin versus 3. 4% for Bruker Corporation — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WAT leads at 28. 2% versus 7. 5% for BRKR. At the gross margin level — before operating expenses — WAT leads at 57. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BRKR or WAT more undervalued right now?
On forward earnings alone, Bruker Corporation (BRKR) trades at 18.
0x forward P/E versus 23. 8x for Waters Corporation — 5. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BRKR: 37. 1% to $52. 13.
08Which pays a better dividend — BRKR or WAT?
In this comparison, BRKR (0.
5% yield) pays a dividend. WAT does not pay a meaningful dividend and should not be held primarily for income.
09Is BRKR or WAT better for a retirement portfolio?
For long-horizon retirement investors, Waters Corporation (WAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
07), +161. 3% 10Y return). Bruker Corporation (BRKR) carries a higher beta of 1. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (WAT: +161. 3%, BRKR: +46. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BRKR and WAT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
BRKR pays a dividend while WAT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.